Technology Bundle ID
TAB-3390

Therapeutic and Diagnostic Targets for Severe RSV Infection

Linked ID
E-072-2019-0
Lead Inventors
Michael Resnick (NIEHS)
Co-Inventors
Daniel Menendez Rendon (NIEHS)
Steven Kleeberger (NIEHS)
Therapeutic Areas
Infectious Disease
ICs
NIEHS
Respiratory Syncytial Virus (RSV) infects nearly all children by their second birthday. RSV usually causes mild respiratory illness, however, a subset of patients experience severe infection that require hospitalization. Successful host defense against viral pathogens requires rapid recognition of the virus and activation of both innate and adaptive immunity. Toll-Like Receptors (TLRs) are responsible for mounting an innate immune response and genetic variations within TLRs modulate severity of infection. Researchers at NIEHS have identified a single nucleotide polymorphism (SNP) in TLR8 that is associated with RSV disease severity. The SNP is p53-responsive allele, indicating that p53, a master cell cycle regulator, can strongly influence TLR8 mediated immune responses. Identification of this SNP can inform diagnosis and prognosis of RSV disease and serve as a therapeutic target for severe RSV infection.
Commercial Applications
  • Development of therapeutics against severe RSV infection
  • Diagnostic biomarker
Competitive Advantages
  • Enhance the innate immune response to respiratory infection
  • Improve clinical trial outcome in patients with TLR8 mediated RSV infection

Request More Info

Licensing Contact: